CVHealthcare · Medical DevicesThe 2 Wall Street analysts covering CapsoVision, Inc. hold a median 12-month price target of $9.5 — +39.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores CapsoVision, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (62): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +39.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Mar 2026 | Benchmark | Maintains | Speculative Buy | $14 → $10 |
| 31 Dec 2025 | Benchmark | Maintains | Speculative Buy | — |
| 28 July 2025 | Benchmark | Initiates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CV appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, CapsoVision, Inc. returned +45.3% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 7% of US stocks
Cheaper than 4% of US stocks
Cheaper than 86% of US stocks
Higher than 52% of US stocks
Higher than 63% of US stocks
Higher than 11% of US stocks
Higher than 2% of US stocks
Higher than 5% of US stocks
Higher than 2% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CapsoVision, Inc. has a market value of $363.4M and an enterprise value of $333.4M.
Revenue in the twelve months to 30 June 2026: $13.9M. The latest quarter grew 9.9% year on year.
Net income over the same four quarters: −$29.8M, a −214.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$27.9M.
Trailing P/E: −6.7×; forward P/E: −15.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CapsoVision, Inc. employs 99 people — $140K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CapsoVision, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CapsoVision announced it will release its third-quarter 2026 financial results on November 12, 2026, after the market closes.
Why it matters — CV watchers can note the scheduled date for the company’s upcoming quarterly financial results.
CapsoVision outlined a strategy to expand its capsule endoscopy technology beyond its current small-bowel business into colon, pancreatic and esophageal cancer screening. The company highlighted AI capabilities, cloud-based workflow and upcoming regulatory submissions.
Why it matters — CV watchers may track the planned expansion into additional screening applications and the associated regulatory submissions.
CapsoVision announced that CEO Johnny Wang, SVP of Finance David Garcia, and SVP of Global Sales Doug Atkinson will present at the 20th Annual LD Micro Main Event. The event is scheduled for October 19–21, 2026, at the Luxe Sunset Boulevard Hotel in Los Angeles.
Why it matters — The presentation is a scheduled opportunity for CapsoVision executives to discuss the company at an investor event.
CapsoVision announced that the FDA has cleared its AI Highlights feature, an AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus system.
Why it matters — This FDA clearance for AI Highlights extends the capability of CapsoCam Plus, potentially enhancing the product's clinical utility for CV watchers.
CapsoVision, Inc. announced that its President and CEO Johnny Wang, Senior Vice President of Finance David Garcia, and Senior Vice President of Global Sales Doug Atkinson plan to participate in upcoming investor conferences, including H.C. Wainwright conferences.
Why it matters — The company's leadership team will present at investor conferences, giving CapsoVision watchers opportunities to hear directly about the company's capsule endoscopy business.
The 2 Wall Street analysts covering CapsoVision, Inc. have a median 12-month price target of $9.5, with estimates ranging from $9 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering CapsoVision, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CapsoVision, Inc. 21 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, CapsoVision, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (62 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +39.1% from the last close, and Ticker Nerd's factor model ranks CapsoVision, Inc. 21 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CapsoVision, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $10 over the next 12 months.
CapsoVision, Inc. returned +45.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
CapsoVision, Inc. is a commercial-stage medical technology company that develops, manufactures, and markets capsule endoscopy systems for gastrointestinal imaging.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026". CapsoVision announced it will release its third-quarter 2026 financial results on November 12, 2026, after the market closes.
CapsoVision, Inc. is a commercial-stage medical technology company that develops, manufactures, and markets capsule endoscopy systems for gastrointestinal imaging. The company’s products are designed to help clinicians visualize the GI tract for diagnostic and screening purposes, with a focus on detecting abnormalities such as bleeding, inflammation, and polyps. Its portfolio includes the CapsoCam Plus capsule endoscopy system for small-bowel visualization, along with cloud-based and direct-view software tools that support image retrieval and review. CapsoVision also offers solutions for colon imaging and related GI applications, combining advanced imaging with AI-enabled workflows to improve clinical efficiency. Based in Saratoga, California, CapsoVision serves hospitals, gastroenterology practices, and other medical providers seeking non-invasive tools for internal GI diagnostics.
CEO Mr. Kang-Huai Wang · 99 employees · United States · https://capsovision.com
